Millennium Management’s Gain Therapeutics GANX Stock Holding History

Millennium Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,002	Closed	-$45.1K	–	5938
2025 Q4	$45.1K	Buy	+14,002	New	+$37.4K	﹤0.01%	5746
2024 Q3	–	Sell	-23,373	Closed	-$29.9K	–	6225
2024 Q2	$29.9K	Sell	23,373 -21,043	-47%	-$54.6K	﹤0.01%	5480
2024 Q1	$167K	Buy	44,416 +31,652	+248%	+$131K	﹤0.01%	5435
2023 Q4	$41.7K	Buy	+12,764	New	+$35.5K	﹤0.01%	5509
2023 Q3	–	Sell	-12,562	Closed	-$56.3K	–	6268
2023 Q2	$56.3K	Buy	+12,562	New	+$61.3K	﹤0.01%	5450
2022 Q2	–	Sell	-10,808	Closed	-$44K	–	7141
2022 Q1	$44K	Sell	10,808 -4,946	-31%	-$20.7K	﹤0.01%	6431
2021 Q4	$84K	Buy	+15,754	New	+$109K	﹤0.01%	6319
2021 Q3	–	Sell	-23,878	Closed	-$239K	–	6937
2021 Q2	$239K	Buy	23,878 +9,511	+66%	+$107K	﹤0.01%	5903
2021 Q1	$214K	Buy	+14,367	New	+$189K	﹤0.01%	5455

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millennium Management's GANX Position: Q1 2026 in Review

Millennium Management sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 14,002 shares — an estimated $45.1K sold.

Millennium Management first reported a position in GANX in Q1 2021 and held it in 9 quarters. The position peaked at $239K in Q2 2021. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Millennium Management reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 14,002 Gain Therapeutics shares in Q1 2026, an estimated $45.1K.
Millennium Management first reported a position in Gain Therapeutics in Q1 2021 and held it in 9 quarters.
Millennium Management's Gain Therapeutics position peaked at $239K in Q2 2021.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.